Anagrelide for thrombocytosis in myeloproliferative disorders: A prospective study to assess efficacy and adverse event profile

Cancer

Volumn 101, Issue 10, 2004, Pages 2239-2246

  Steurer, Michael ^a   Gastl, Guenther ^a   Jedrzejczak, Wieslaw Wiktor ^b   Pytlik, Robert ^c   Lin, Werner ^d   Schlögl, Ernst ^e   Gisslinger, Heinz ^e  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Landeskrankenhaus Villach ^*  (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anagrelide; Essential thrombocythemia; Idiopathic myelofibrosis; Polycythemia vera; Thromboembolic complications

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; MELPHALAN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CLINICAL TRIAL; COHORT ANALYSIS; COMMON COLD; CONGESTIVE HEART FAILURE; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EPISTAXIS; FATIGUE; FEMALE; GINGIVA BLEEDING; HEADACHE; HEART PALPITATION; HEMATOMA; HUMAN; INTESTINE HEMATOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE WEAKNESS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SIDE EFFECT; STROKE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PLATELET COUNT; QUINAZOLINES; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 7644244584     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20646     Document Type: Article

References (28)

1. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
2. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythaemia and high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
3. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J. Treatment strategies in essential thrombocythaemia: a critical appraisal of various experiences in different centres. Leuk Lymphoma. 1996;22(Suppl. 1):149-160.
4. Gruppo Italiano Studio Policitemia (GISP). Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
5. Lahuerta-Palacios JJ, Bornstein R, Fernandez-Debora FJ, et al. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer. 1988;61:1207-1212.
6. Millard FE, Hunter CS, Anderson M, et al. Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol. 1990;33:27-31.
7. Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989;25:634-637.
8. Sterkens Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythaemia treated with hydroxyurea: high proportion of cases with 17 p depletion. Blood. 1998;91:616-622.
9. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Interferon in essential thrombocythaemia. Brit J Haematol. 1991;79(Suppl 1):42-47.
10. Heis N, Rintelen C, Gisslinger B, Knöbl P, Lechner K, Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol. 1999;62:27-31.
11. Silverstein MN, Petitt RM, Solberg LA Jr., Felming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med. 1988;318:1292-1294.
12. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Hematologica. 1992;77:40-43.
13. Anagrelide study group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992; 92:69-76.
14. Storen EC, Tefferi A. Long term use of anagrelide in young patients with essential thrombocythaemia. Blood. 2001;97: 863-866.
15. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica. 1992;77:315-317.
16. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia and polycythemia and other myeloproliferative disorders. Semin Hematol. 1997;34:51-54.
17. Burkhard R, Adam H, Widmer L, Honegger HP. Anagrelide zur Kontrolle der myeloproliferativen Thrombozythämie: Langzeiterfahrung bei 6 Patienten (Anagrelide in control of myelopeoliferative thrombocythemia: long-term experiences in 6 patients). Schweiz Med Wochenschr. 1998;128: 1808-1812.
18. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol. 1998;61:71-76.
19. Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythemia. Aust N Z J Med. 1999;29:29-37.
20. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost. 2000;6:157-161.
21. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22-28.
22. 9/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1998;100:15-23.
23. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol. 2000;79:312-318.
24. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350:114-124.
25. Pescatore SL, Lindley C. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother. 2000;1:537-546.
26. Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm. 1998;55:1979-1986.
27. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br J Haematol. 1999;104:886-892.
28. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997;97:179-184.